# Stoke Therapeutics, Inc. (STOK) FY2026 YTD Q2 P&L / Income Statement

- Company: Stoke Therapeutics, Inc. (STOK)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001193125-26-330557
- Page: https://plicit.ai/financials/stok/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/stok-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Arrangement

Income statement for 2026-01-01 through 2026-06-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 15,554,000 US dollars
- **Total operating expenses**: 134,401,000 US dollars
- **(Loss) income from operations**: negative 118,847,000 US dollars
- **Total other income (expense)**: 7,226,000 US dollars
- **(Loss) income before income taxes**: negative 111,621,000 US dollars
- **Provision for income taxes**: 0 US dollars
- **Net (loss) income**: negative 111,621,000 US dollars
- **Global Development Activity - Biogen License Agreement**: 10,563,000 US dollars
- **IP License - Biogen License Agreement**: 0 US dollars
- **Undisclosed (calculated)**: 4,991,000 US dollars
- **Total operating expenses**: 134,401,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Arrangement

- Page: https://plicit.ai/financials/stok/fy2026-ytd-q2-income-statement/revenue-by-arrangement
- Chart image: https://plicit.ai/charts/stok-fy2026-ytd-q2-revenue-by-arrangement-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 15,554,000 US dollars
- **Total operating expenses**: 134,401,000 US dollars
- **(Loss) income from operations**: negative 118,847,000 US dollars
- **Total other income (expense)**: 7,226,000 US dollars
- **(Loss) income before income taxes**: negative 111,621,000 US dollars
- **Provision for income taxes**: 0 US dollars
- **Net (loss) income**: negative 111,621,000 US dollars
- **Acadia Agreement**: 5,000,000 US dollars
- **Biogen License Agreement**: 10,563,000 US dollars
- **Total operating expenses**: 134,401,000 US dollars
- **Revenue before reconciliation (calculated)**: 15,563,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Components above reported revenue (calculated)**: negative 9,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.